These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 25724760)

  • 21. Glutamatergic drugs for schizophrenia treatment.
    Gibert-Rahola J; Villena-Rodriguez A
    Actas Esp Psiquiatr; 2014; 42(5):234-41. PubMed ID: 25179095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glutamatergic drugs for schizophrenia.
    Tuominen HJ; Tiihonen J; Wahlbeck K
    Cochrane Database Syst Rev; 2006 Apr; (2):CD003730. PubMed ID: 16625590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. mGlu₅-GABAB interplay in animal models of positive, negative and cognitive symptoms of schizophrenia.
    Wierońska JM; Kłeczek N; Woźniak M; Gruca P; Łasoń-Tyburkiewicz M; Papp M; Brański P; Burnat G; Pilc A
    Neurochem Int; 2015 Sep; 88():97-109. PubMed ID: 25863284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia.
    Heresco-Levy U
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):827-44. PubMed ID: 16262565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists.
    Krystal JH; Mathew SJ; D'Souza DC; Garakani A; Gunduz-Bruce H; Charney DS
    CNS Drugs; 2010 Aug; 24(8):669-93. PubMed ID: 20658799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antischizophrenic activity independent of dopamine D2 blockade.
    Kalkman HO
    Expert Opin Ther Targets; 2002 Oct; 6(5):571-82. PubMed ID: 12387681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Novel Metabotropic Glutamate Receptor 2 Positive Allosteric Modulator, AZD8529, Decreases Nicotine Self-Administration and Relapse in Squirrel Monkeys.
    Justinova Z; Panlilio LV; Secci ME; Redhi GH; Schindler CW; Cross AJ; Mrzljak L; Medd A; Shaham Y; Goldberg SR
    Biol Psychiatry; 2015 Oct; 78(7):452-62. PubMed ID: 25802079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Group II metabotropic glutamate receptors and schizophrenia.
    Moreno JL; Sealfon SC; González-Maeso J
    Cell Mol Life Sci; 2009 Dec; 66(23):3777-85. PubMed ID: 19707855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Juvenile treatment with a novel mGluR2 agonist/mGluR3 antagonist compound, LY395756, reverses learning deficits and cognitive flexibility impairments in adults in a neurodevelopmental model of schizophrenia.
    Li ML; Gulchina Y; Monaco SA; Xing B; Ferguson BR; Li YC; Li F; Hu XQ; Gao WJ
    Neurobiol Learn Mem; 2017 Apr; 140():52-61. PubMed ID: 28213064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia?
    DD DD; Marek GJ
    Curr Drug Targets CNS Neurol Disord; 2002 Apr; 1(2):215-25. PubMed ID: 12769628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biological perspectives: the role of glutamate in schizophrenia and its treatment.
    Steele D; Moore RL; Swan NA; Grant JS; Keltner NL
    Perspect Psychiatr Care; 2012 Jul; 48(3):125-8. PubMed ID: 22724397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversal of MK-801-Induced Disruptions in Social Interactions and Working Memory with Simultaneous Administration of LY487379 and VU152100 in Mice.
    Cieślik P; Radulska A; Pelikant-Małecka I; Płoska A; Kalinowski L; Wierońska JM
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31174329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutual activation of glutamatergic mGlu
    Cieślik P; Woźniak M; Rook JM; Tantawy MN; Conn PJ; Acher F; Tokarski K; Kusek M; Pilc A; Wierońska JM
    Psychopharmacology (Berl); 2018 Oct; 235(10):2897-2913. PubMed ID: 30054675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disturbed function of GABAergic interneurons in schizophrenia: relevance for medical treatment?
    Genius J; Giegling I; Benninghoff J; Rujescu D
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1549-56. PubMed ID: 22283755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological characterization of metabotropic glutamate receptors in several types of brain cells in primary cultures.
    Prézeau L; Carrette J; Helpap B; Curry K; Pin JP; Bockaert J
    Mol Pharmacol; 1994 Apr; 45(4):570-7. PubMed ID: 8183235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations.
    Petralia RS; Wang YX; Niedzielski AS; Wenthold RJ
    Neuroscience; 1996 Apr; 71(4):949-76. PubMed ID: 8684625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): efficacy in an animal model for schizophrenia.
    Govek SP; Bonnefous C; Hutchinson JH; Kamenecka T; McQuiston J; Pracitto R; Zhao LX; Gardner MF; James JK; Daggett LP; Rowe BA; Schaffhauser H; Bristow LJ; Campbell UC; Rodriguez DE; Vernier JM
    Bioorg Med Chem Lett; 2005 Sep; 15(18):4068-72. PubMed ID: 16005222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity.
    Schlumberger C; Pietraszek M; Gravius A; Klein KU; Greco S; Morè L; Danysz W
    Eur J Pharmacol; 2009 Nov; 623(1-3):73-83. PubMed ID: 19765575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia.
    Griebel G; Pichat P; Boulay D; Naimoli V; Potestio L; Featherstone R; Sahni S; Defex H; Desvignes C; Slowinski F; Vigé X; Bergis OE; Sher R; Kosley R; Kongsamut S; Black MD; Varty GB
    Sci Rep; 2016 Oct; 6():35320. PubMed ID: 27734956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Targeting metabotropic glutamate receptors to develop novel antipsychotics].
    Chaki S; Yoshida S; Okuyama S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):207-13. PubMed ID: 21226317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.